Xenon in the treatment of panic disorder: an open-label study

Trial Profile

Xenon in the treatment of panic disorder: an open-label study

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Oxygen (Primary) ; Xenon (Primary)
  • Indications Panic disorder
  • Focus Therapeutic Use
  • Sponsors Nobilis Therapeutics
  • Most Recent Events

    • 14 Jun 2017 According to a Nobilis Therapeutics, Inc. media release, results from this study were published in Journal of Translational Medicine.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top